RxDoctor Payments Data

Justin Yancey, DO

Nephrology · Germantown, TNNPI 1013390467

Payments from drug & device makers

$2,975in general payments, 2019–2025

Across 132 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$658
  • Lilly USA, LLC$364
  • AstraZeneca$349
  • Vifor Pharma, Inc.$327
  • Travere Therapeutics, Inc.$255
  • Otsuka America Pharmaceutical, Inc.$236
  • plus $787 from 10 others

What the payments were for

  • Food & beverage$2,76093%
  • Education$2157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,975 in reported general payments places this provider in the 65th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$468,783
Medicare patients
849
Services billed
5,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide57$172,041
FarxigaDapagliflozin Propanediol43$35,723
Sevelamer Carbonate62$19,716
LokelmaSodium Zirconium Cyclosilicate13$7,740
Midodrine Hcl11$829
Lidocaine-PrilocaineLidocaine/Prilocaine14$751
Hydralazine Hcl48$633
Amlodipine Besylate78$434
Isosorbide Mononitrate ErIsosorbide Mononitrate13$312
Losartan Potassium45$305
Allopurinol33$259
Carvedilol51$259
Potassium Chloride13$171
Furosemide38$136
Clonidine Hcl17$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$96$172,04157 claims
AstraZenecaFarxiga, Lokelma$349$43,46356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →